electroCore, Inc.
NASDAQ:ECOR

Watchlist Manager
electroCore, Inc. Logo
electroCore, Inc.
NASDAQ:ECOR
Watchlist
Price: 16.0433 USD -1.33%
Market Cap: 105.1m USD
Have any thoughts about
electroCore, Inc.?
Write Note

electroCore, Inc.
Accounts Payable

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

electroCore, Inc.
Accounts Payable Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Accounts Payable CAGR 3Y CAGR 5Y CAGR 10Y
electroCore, Inc.
NASDAQ:ECOR
Accounts Payable
$1.2m
CAGR 3-Years
-2%
CAGR 5-Years
-26%
CAGR 10-Years
N/A
Becton Dickinson and Co
NYSE:BDX
Accounts Payable
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Boston Scientific Corp
NYSE:BSX
Accounts Payable
$907m
CAGR 3-Years
10%
CAGR 5-Years
12%
CAGR 10-Years
15%
Stryker Corp
NYSE:SYK
Accounts Payable
$1.3B
CAGR 3-Years
13%
CAGR 5-Years
15%
CAGR 10-Years
15%
Abbott Laboratories
NYSE:ABT
Accounts Payable
$4B
CAGR 3-Years
0%
CAGR 5-Years
6%
CAGR 10-Years
15%
Intuitive Surgical Inc
NASDAQ:ISRG
Accounts Payable
$218.7m
CAGR 3-Years
22%
CAGR 5-Years
11%
CAGR 10-Years
15%
No Stocks Found

electroCore, Inc.
Glance View

Market Cap
104.4m USD
Industry
Health Care

electroCore, Inc. engages in the provision of non-invasive vagus nerve stimulation (nVNS) therapy. The company is headquartered in Rockaway, New Jersey and currently employs 52 full-time employees. The company went IPO on 2018-06-22. nVNS is a platform for bioelectronic medical therapy that modulates neurotransmitters and immune function through its effects on both the peripheral and central nervous systems. The firm is providing gammaCore device for the treatment of cluster headache and migraine, the acute treatment of migraine and episodic cluster headache, the acute and preventive treatment of migraines in adolescents, and paroxysmal hemicrania and hemicrania continua in adults. gammaCore permits patients to self-administer doses of nVNS on an as-needed basis for treatment of prevent multiple types of headache pain via the vagus nerve. The gammaCore therapy is also used to treat primary headache, including migraine, cluster headache (CH), hemicrania continua and paroxysmal hemicrania (PH) and coronavirus (COVID-19).

ECOR Intrinsic Value
18.4922 USD
Undervaluation 13%
Intrinsic Value
Price

See Also

What is electroCore, Inc.'s Accounts Payable?
Accounts Payable
1.2m USD

Based on the financial report for Sep 30, 2024, electroCore, Inc.'s Accounts Payable amounts to 1.2m USD.

What is electroCore, Inc.'s Accounts Payable growth rate?
Accounts Payable CAGR 5Y
-26%

Over the last year, the Accounts Payable growth was -59%. The average annual Accounts Payable growth rates for electroCore, Inc. have been -2% over the past three years , -26% over the past five years .

Back to Top